CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...